Engraftment of investigational microbiome drug, SER-262, in subjects receiving vancomycin is associated with reduced rates of recurrence after primary clostridium difficile infection (CDI)

Category Primary study
JournalOpen Forum Infectious Diseases
Year 2019
This article has no abstract
Epistemonikos ID: 6a72f688a74625ea8e8094c6926dace466b0b650
First added on: Feb 11, 2025